Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7496082 | 0.88 | KCNH2 (0.48) | ADRB2KCNH2TDP1LMNAMEN1 | |
| SCHEMBL2903740 | 0.86 | KCNH2 (0.50) | KCNH2TDP1MEN1KMT2AALOX15 | |
| SCHEMBL7507103 | 0.85 | ADRB2 (0.55) | ADRB2KCNH2TDP1LMNAKMT2A | |
| SCHEMBL4297280 | 0.85 | ADRB2 (0.54) | ADRB2KCNH2TDP1KMT2AALOX15 | |
| SCHEMBL5733629 | 0.84 | ADRB2 (0.48) | ADRB2KCNH2TDP1LMNAMEN1 | |
| SCHEMBL7122628 | 0.83 | KCNH2 (0.44) | ADRB2KCNH2TDP1LMNAMEN1 | |
| SCHEMBL5733501 | 0.83 | TOP2A (0.45) | ADRB2KCNH2TDP1MEN1MAPT | |
| SCHEMBL7504273 | 0.83 | ADRB2 (0.47) | ADRB2KCNH2TDP1LMNAMEN1 | |
| SCHEMBL1984659 | 0.82 | ADRB2 (0.58) | ADRB2KCNH2TDP1KMT2AALOX15 | |
| SCHEMBL7500713 | 0.82 | ADRB2 (0.47) | ADRB2KCNH2TDP1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105777631-A | Synthesizing method of 1-cyclopropyl-4-oxo-7-bromo-8-difluoromethoxy-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester | 浙江中欣氟材股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
| CN-105777631-A | Synthesizing method of 1-cyclopropyl-4-oxo-7-bromo-8-difluoromethoxy-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester | 浙江中欣氟材股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
| EP-1861401-B1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-18 | — | — | EP | disclosed |
| WO-2013121439-A2 | PROCESS FOR GARENOXACIN MESYLATE | GLENMARK GENERICS LIMITED (IN) | 2013-08-22 | — | — | WO | disclosed |
| WO-2011124093-A1 | BICYCLIC QUINOLONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | 山东轩竹医药科技有限公司 (CN) | 2011-10-13 | — | — | WO | disclosed |
| US-7902226-B2 | Dehalogeno-compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7732612-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7732612-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| WO-2010056633-A2 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-20 | — | — | WO | disclosed |
| EP-1031569-B1 | SALT OF A 7-ISOINDOLINEQUINOLONECARBOXYLIC ACID DERIVATIVE, MONOHYDRATE THEREOF AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO LTD (JP) | 2010-03-17 | — | — | EP | disclosed |
| EP-0882725-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-6482835-B2 | SUCH AS (R)-1-CYCLOPROPYL-8-DIFLUOROMETHOXY-7-(1-METHYL-2,3-DIHYDRO-1H-5-ISOINDOLYL)-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXYL IC ACID METHANESULFONATE; CHEMICAL INTERMEDIATES; BACTERICIDES; CATALYSIS | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | ABBOTT LABORATORIES | 2002-04-25 | — | — | US | disclosed |
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6337399-B1 | CONDENSATION OF ISOINDOLE WITH BORATE GROUP WITH QUINOLONE CARBOXYLIC ACID | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6316658-B1 | QUINOLONE CARBOXYLATE CHEMICAL INTERMEDIATES; MICROBIOCIDES, BACTERICIDES | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| EP-1031555-A1 | N-CYCLOPROPYL-2-DIFLUOROMETHOXY-3-HALOGENOANILINES AND INTERMEDIATES FOR THE PREPARATION THEREOF | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2000-08-30 | — | — | EP | disclosed |
| EP-1031569-A1 | PROCESSES FOR PRODUCING 7-ISOINDOLINEQUINOLONECARBOXYLIC DERIVATIVES AND INTERMEDIATES THEREFOR, SALTS OF 7-ISOINDOLINEQUINOLONECARBOXYLIC ACIDS, HYDRATES THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
| US-6025370-A | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0882725-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | NQO2, NQO1, NDUFA7 | ADRB2 3198/4885KCNH2 2211/4885TDP1 2273/4885 |
| US-20020049328-A1 | Processes for producing 7-isoindoline-quinolonecarboxylic acid derivative and its intermediate, as well as salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and composition comprising the same as active ingredient | BRD7, IMPDH1, DDT | ADRB2 1117/4885KCNH2 979/4885TDP1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.